RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study
2023-01-01 Ciccarese, Chiara; Buti, Sebastiano; Roberto, Michela; Calabro, Fabio; Masini, Cristina; Massari, Francesco; Cannella, Maria Antonella; Mazzaschi, Giulia; Astore, Serena; Di Girolamo, Stefania; Panebianco, Martina; Mollica, Veronica; Granitto, Alessia; Fiorentino, Vincenzo; Pierconti, Francesco; Martini, Maurizio; Porta, Camillo; Tortora, Giampaolo; Iacovelli, Roberto
Factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC): Preliminary results of HOPLITE trial
2012-01-01 Caffo, O; Lo Re, G; Sava, T; Buti, S; Sacco, C; Basso, U; Zustovich, F; Martini, T; Perin, A; Veccia, A; Russo, L; Facchini, G; Barile, C; Gernone, A; Pappagallo, Gl; Galligioni, E
Feasibility of two sequential dose-dense regimens with cisplatin-gemcitabine-paclitaxel (CGP) and HD-MVAC in patients with metastatic transitional cell carcinoma of the bladder
2010-01-01 Brighenti, M; Liguigli, W; dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Lazzarelli, S; Poli, R; Donnini, M; Curti, A; Passalacqua, R; Potenzoni, D; Benecchi, L
Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial)
2022-01-01 Porcari, Serena; Ciccarese, Chiara; Pinto, Federica; Quaranta, Gianluca; De Giorgi, Silvia; Rondinella, Debora; Settanni, Carlo Romano; Cortesi, Enrico; Roberto, Michela; Primi, Francesca; Buti, Sebastiano; Fornarini, Giuseppe; Masucci, Luca; Sanguinetti, Maurizio; Gasbarrini, Antonio; Tortora, Giampaolo; Cammarota, Giovanni; Segata, Nicola; Iacovelli, Roberto; Ianiro, Gianluca
Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (MRCC): Bevacizumab (B) plus Immunotherapy (I) plus Chemotherapy (C) (BIC). Antitumor effects and variations of circulating T-regulatory cells (Treg) and other T lymphocytes subsets
2009-01-01 Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Dalla Chiesa, M; Tomasello, G; Negri, F; Lazzarelli, S
Final results of dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG)
2010-01-01 Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Lazzarelli, S
First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): The ARIES trial
2022-01-01 Iacovelli, Roberto; Ciccarese, Chiara; Brunelli, Matteo; Battelli, Nicola; Buttigliero, Consuelo; Caserta, Claudia; Buti, Sebastiano; Santini, Daniele; Naglieri, Emanuele; Galli, Luca; Verri, Elena; Ermacora, Paola; Milella, Michele; Masini, Cristina; Aprile, Giuseppe; Milesi, Laura; Spina, Francesco; Rizzo, Mimma; Sperduti, Isabella; Fornarini, Giuseppe
FIRST LINE AVELUMAB IN PD-L1+VE METASTATIC OR LOCALLY ADVANCED UROTHELIAL CANCER (AUC) PATIENTS UNFIT FOR CISPLATIN (CIS): THE ARIES TRIAL
2022-01-01 Ciccarese, C; Brunelli, M; Battelli, N; Buttigliero, C; Caserta, C; Buti, S; Santini, D; Naglieri, E; Galli, L; Verri, E; Ermacora, P; Milella, M; Masini, C; Aprile, G; Milesi, L; Spina, F; Rizzo, M; Sperduti, I; Fornarini, G; Iacovelli, R
Gefitinib (G) plus Interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC)
2007-01-01 Tomasello, G; Buti, S; Bosio, G; Stifani, I; Maestrelli, M; Brighenti, M; Porzio, R; Lazzarelli, S; Negri, F; Longarini, R; Passalacqua, R
Gefitinib plus interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC)
2005-01-01 Buti, S; Chiesa, Md; Tomasello, G; Negri, F; Machiavelli, A; Bosio, G; Stifani, I; Betti, M; Buononato, M; Passalacqua, R
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study | 1-gen-2023 | Ciccarese, Chiara; Buti, Sebastiano; Roberto, Michela; Calabro, Fabio; Masini, Cristina; Massari, Francesco; Cannella, Maria Antonella; Mazzaschi, Giulia; Astore, Serena; Di Girolamo, Stefania; Panebianco, Martina; Mollica, Veronica; Granitto, Alessia; Fiorentino, Vincenzo; Pierconti, Francesco; Martini, Maurizio; Porta, Camillo; Tortora, Giampaolo; Iacovelli, Roberto | |
Factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC): Preliminary results of HOPLITE trial | 1-gen-2012 | Caffo, O; Lo Re, G; Sava, T; Buti, S; Sacco, C; Basso, U; Zustovich, F; Martini, T; Perin, A; Veccia, A; Russo, L; Facchini, G; Barile, C; Gernone, A; Pappagallo, Gl; Galligioni, E | |
Feasibility of two sequential dose-dense regimens with cisplatin-gemcitabine-paclitaxel (CGP) and HD-MVAC in patients with metastatic transitional cell carcinoma of the bladder | 1-gen-2010 | Brighenti, M; Liguigli, W; dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Lazzarelli, S; Poli, R; Donnini, M; Curti, A; Passalacqua, R; Potenzoni, D; Benecchi, L | |
Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial) | 1-gen-2022 | Porcari, Serena; Ciccarese, Chiara; Pinto, Federica; Quaranta, Gianluca; De Giorgi, Silvia; Rondinella, Debora; Settanni, Carlo Romano; Cortesi, Enrico; Roberto, Michela; Primi, Francesca; Buti, Sebastiano; Fornarini, Giuseppe; Masucci, Luca; Sanguinetti, Maurizio; Gasbarrini, Antonio; Tortora, Giampaolo; Cammarota, Giovanni; Segata, Nicola; Iacovelli, Roberto; Ianiro, Gianluca | |
Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (MRCC): Bevacizumab (B) plus Immunotherapy (I) plus Chemotherapy (C) (BIC). Antitumor effects and variations of circulating T-regulatory cells (Treg) and other T lymphocytes subsets | 1-gen-2009 | Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Dalla Chiesa, M; Tomasello, G; Negri, F; Lazzarelli, S | |
Final results of dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG) | 1-gen-2010 | Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Lazzarelli, S | |
First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): The ARIES trial | 1-gen-2022 | Iacovelli, Roberto; Ciccarese, Chiara; Brunelli, Matteo; Battelli, Nicola; Buttigliero, Consuelo; Caserta, Claudia; Buti, Sebastiano; Santini, Daniele; Naglieri, Emanuele; Galli, Luca; Verri, Elena; Ermacora, Paola; Milella, Michele; Masini, Cristina; Aprile, Giuseppe; Milesi, Laura; Spina, Francesco; Rizzo, Mimma; Sperduti, Isabella; Fornarini, Giuseppe | |
FIRST LINE AVELUMAB IN PD-L1+VE METASTATIC OR LOCALLY ADVANCED UROTHELIAL CANCER (AUC) PATIENTS UNFIT FOR CISPLATIN (CIS): THE ARIES TRIAL | 1-gen-2022 | Ciccarese, C; Brunelli, M; Battelli, N; Buttigliero, C; Caserta, C; Buti, S; Santini, D; Naglieri, E; Galli, L; Verri, E; Ermacora, P; Milella, M; Masini, C; Aprile, G; Milesi, L; Spina, F; Rizzo, M; Sperduti, I; Fornarini, G; Iacovelli, R | |
Gefitinib (G) plus Interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC) | 1-gen-2007 | Tomasello, G; Buti, S; Bosio, G; Stifani, I; Maestrelli, M; Brighenti, M; Porzio, R; Lazzarelli, S; Negri, F; Longarini, R; Passalacqua, R | |
Gefitinib plus interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC) | 1-gen-2005 | Buti, S; Chiesa, Md; Tomasello, G; Negri, F; Machiavelli, A; Bosio, G; Stifani, I; Betti, M; Buononato, M; Passalacqua, R |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 1 Articolo su rivista 113
- 1 Articolo su rivista::1.5 Abstra... 113
Data di pubblicazione
- 2020 - 2023 38
- 2010 - 2019 45
- 2004 - 2009 30
Editore
- ASCO pubs 11
- Elsevier 6
- SAGE PUBLICATIONS LTD 5
- ELSEVIER 4
- BioMed Central 2
- International Institute of Antica... 1
- LIPPINCOTT WILLIAMS & WILKINS 1
- SAGE 1
Rivista
- ANNALS OF ONCOLOGY 39
- JOURNAL OF CLINICAL ONCOLOGY 39
- TUMORI 8
- I SUPPLEMENTI DI TUMORI 5
- JOURNAL OF THORACIC ONCOLOGY 4
- JOURNAL OF CLINICAL ONCOLOGY 3
- ANTICANCER RESEARCH 2
- GIORNALE ITALIANO DI NEFROLOGIA 2
- JOURNAL FOR IMMUNOTHERAPY OF CANCER 2
- ANTICANCER RESEARCH 1
Keyword
- Poster presentation at AIOM 2022 1
Lingua
- eng 95
- ita 4
- fre 1
Accesso al fulltext
- no fulltext 110
- open 3